On Monday, Shares of Advanced Micro Devices, Inc. (NASDAQ:AMD), lost -7.66% to $1.93.
The company traded at $1.93 per share, which was -7.66% less compared to what it had traded at previously. The company had suffered a one-year low on Jul 27, 2015, and gradually it is picking up from there. On a volatile Monday, the company opened at $1.90, and went on to $1.98. The day ended at $1.93 for the company. Last 4-weeks performance indicates that the shares lost almost -1.53% or -$0.03.
Advanced Micro Devices, Inc. operates as a semiconductor company worldwide. The company’s products primarily comprise x86 microprocessors as an accelerated processing unit (APU), chipsets, discrete graphics processing units (GPUs), and semi-custom System-on-Chip (SoC) products.
Shares of Mondelez International, Inc. (NASDAQ:MDLZ), inclined 0.65% to $46.41, during its last trading session, after Warren Buffett denied any possible acquisition by the newly-formed Kraft Heinz (KHC), The Wall Street Journal reports.
“At Kraft Heinz, we have our work cut out for us for a couple of years,” Buffet said on CNBC this morning.
“Frankly, most of the food companies sell at prices that it would be very hard for us to make a deal even if we had done all the work needed at Kraft Heinz,” he added.
Mondelez International, Inc., through its auxiliaries, manufactures and markets snack food and beverage products worldwide. The company offers biscuits, counting cookies, crackers, and salted snacks; chocolates, and gums and candies; powdered beverages and coffee; and cheese and grocery products.
Finally, Aeterna Zentaris Inc. (NASDAQ:AEZS), ended its last trade with -5.67% loss, and closed at $0.16, hitting its lowest level.
Aeterna Zentaris will declare its second quarter 2015 financial and operating results after market close on Thursday, August 13, 2015. The Company will host a conference call to talk about these results on Friday, August 14, 2015, at 8:30 a.m., Eastern Time.
Aeterna Zentaris Inc., a specialty biopharmaceutical company, engages in developing and commercializing novel treatments in oncology, endocrinology, and women’s health. The company’s product pipeline comprises MACRILEN, which accomplished the Phase 2 trial for use in the diagnosis of adult growth hormone deficiency; and zoptarelin doxorubicin, which is in Phase 3 clinical study zoptarelin doxorubicin in endometrial cancer (ZoptEC) of the compound in women with advanced, recurrent, or metastatic endometrial cancer.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties, which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified with such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
